Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

Rhea-AI Summary

Viking Therapeutics, Inc. (VKTX) will release financial results for the fourth quarter and year-end 2023 on February 7, 2024. The company, focused on developing therapies for metabolic and endocrine disorders, will host a conference call to discuss financial results and corporate updates. Participants can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. A telephone replay will be available until February 14, 2024. The conference call can also be accessed live via the internet on Viking's website.

 Conference Call Scheduled for Wednesday, February 7 at 4:30 p.m. Eastern Time

SAN DIEGO, Jan. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2023 after the market close on Wednesday, February 7, 2024.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, February 7, 2024. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until February 14, 2024 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #5763805. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company also recently initiated a Phase 1 study to evaluate an oral formulation of VK2735. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2023-on-february-7-2024-302048468.html

SOURCE Viking Therapeutics, Inc

FAQ

When will Viking Therapeutics release financial results for Q4 and year-end 2023?

Viking Therapeutics will release financial results on February 7, 2024.

What is the focus of Viking Therapeutics as a company?

Viking Therapeutics is focused on developing therapies for metabolic and endocrine disorders.

How can participants join the conference call?

Participants can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S.

Until when will the telephone replay be accessible?

The telephone replay will be accessible until February 14, 2024.

Where can the conference call be accessed live via the internet?

The conference call can be accessed live via the internet on Viking's website at http://ir.vikingtherapeutics.com/webcasts.